- Federal agenciesCentralized, binding federal review authority for high-risk life sciences research improves consistent risk oversight.
- Targeted stakeholdersStandardized biosafety, biosecurity, and personnel requirements across agencies may reduce risky research practices.
- Federal agenciesMandatory attestations and disclosures improve traceability and accountability of federally funded life sciences projec…
Risky Research Review Act
Referred to the Committee on Science, Space, and Technology, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in…
Creates an independent Life Sciences Research Security Board to review and make binding determinations on federal funding for defined high-risk life sciences research (dual-use, gain-of-function, high-consequence pathogens).
Establishes Board membership, conflict-of-interest rules, security clearances, review procedures, applicant attestations, agency referral obligations, enforcement mechanisms, reporting requirements, GAO audits, staff limits, and authorizes $30 million annually for 2026–2035.
Technically specific and security‑oriented, so attractable, but creates new binding federal body and regulatory burden that invites sustained scrutiny and potential opposition.
How solid the drafting looks.
Liberal emphasizes public-health protections and oversight benefits
Who stands to gain, and who may push back.
- Targeted stakeholdersAdds preaward review steps that may delay grant awards and research starts.
- Federal agenciesBinding Board authority may override agency expertise, centralizing federal control over scientific funding.
- Targeted stakeholdersAdditional compliance, attestation, reporting, and subcontractor disclosures increase administrative burden and costs f…
Why the argument around this bill splits.
Liberal emphasizes public-health protections and oversight benefits
Likely broadly supportive of independent oversight to prevent misuse of dangerous biological research while protecting public health.
Would welcome mandatory review, disclosure, and stronger biosafety/security requirements but watch for excessive secrecy or barriers to legitimate public-health research.
Views the bill as a pragmatic step to close oversight gaps around risky research but cautious about duplication, timelines, and operational details.
Would favor amendments ensuring clear coordination, predictable review timelines, and minimized disruption to legitimate research.
Skeptical of creating a new independent agency with binding authority over agency grants; views this as federal overreach that could stifle innovation, impose costs, and politicize science.
May accept targeted measures for national security but oppose broad supervisory powers.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically specific and security‑oriented, so attractable, but creates new binding federal body and regulatory burden that invites sustained scrutiny and potential opposition.
- Level and coordination of scientific community lobbying against provisions
- Agency willingness and logistics to provide classified access and support
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Liberal emphasizes public-health protections and oversight benefits
Technically specific and security‑oriented, so attractable, but creates new binding federal body and regulatory burden that invites sustain…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Risky Research Review Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.